Перевести на Переведено сервисом «Яндекс.Перевод»

Analyst recommendations

The biotechnology sector has been incredibly successful in 2014 year. Its growth outperformed the growth of S&P 500  stunning 36%. Analysts at JP Morgan believe that a huge priority sector dynamics can decrease in 2015 year, but may remain the same level. The main drivers the success of biotech in 2014 were a high demand for the main products of the sector, the positive results of many clinical studies phase a wave of successful initial public offerings.
Date Company Who recommends Recommendation Target price
Waters Corporation BofA/Merrill Buy 140
UnitedHealth Group Incorporated Morgan Stanley Buy 140
Thermo Fisher Scientific, Inc. Argus Buy 145
Universal Health Services Inc. Barclays Buy 150
Vertex Pharmaceuticals Incorporated Argus Buy 155
Celgene Corporation UBS Buy 156
Cigna Corp. Barclays Buy 156
Edwards Lifesciences Corp. RBC Capital Mkts Buy 160
Aetna Inc. BofA/Merrill Buy 162
Becton, Dickinson and Company Deutsche Bank Buy 167
Amgen Inc. Deutsche Bank Buy 180
Anthem, Inc. RBC Capital Mkts Buy 198
Humana Inc. Barclays Buy 223
Alexion Pharmaceuticals, Inc. UBS Buy 223
Allergan plc Deutsche Bank Buy 342
Biogen Inc. Bernstein Buy 360
Regeneron Pharmaceuticals, Inc. Barclays Buy 593
Intuitive Surgical, Inc. Barclays Buy 625
1 2